Idorsia (CHIX:IDIAZ) EBIT: CHF-67.2 Mil (TTM As of Mar. 2026)


CHIX:IDIAZ Idorsia Ltd CHIX:IDIAZ
63 GF Score
Price CHF6.02
GF Value CHF2.88
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia EBIT?

Idorsia CHIX:IDIAZ +3.79% 63 EBIT is CHF-67.2 Mil as of Mar. 2026. GuruFocus rates CHIX:IDIAZ with a GF Score™ of 63/100 and a GF Value™ of CHF2.88 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Idorsia's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was CHF-26.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-67.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Idorsia's annualized ROC % for the quarter that ended in Mar. 2026 was -28.45%. Idorsia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -55.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Idorsia's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2.44%.


Idorsia  (CHIX:IDIAz) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Idorsia's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-106.112 * ( 1 - 1.05% )/( (372.959 + 365.181)/ 2 )
=-104.997824/369.07
=-28.45 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=480.458 - 25.417 - ( 94.697 - max(0, 149.701 - 239.561+94.697))
=365.181

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Idorsia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-106.112/( ( (190.863 + max(-29.903, 0)) + (187.064 + max(2.083, 0)) )/ 2 )
=-106.112/( ( 190.863 + 189.147 )/ 2 )
=-106.112/190.005
=-55.85 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(38.723 + 82.051 + 2.593) - (29.972 + 0 + 123.298)
=-29.903

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(55.258 + 78.298 + 11.308) - (25.417 + 0 + 117.364)
=2.083

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Idorsia's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-67.222/2760.202
=-2.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Idorsia EBIT Related Terms


Idorsia EBIT Historical Data

* Premium members only.

The historical data trend for Idorsia's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idorsia EBIT Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -606.87 -802.92 -273.59 -244.33 -62.93

Idorsia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.24 94.36 -78.70 -56.35 -26.53

CHIX:IDIAZ vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Idorsia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Idorsia EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Idorsia's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Idorsia's EV-to-EBIT falls into.


CHIX:IDIAZ
63GF Score
Idorsia Ltd CHIX:IDIAZ
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idorsia EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-67.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of CHF-67.2 Mil mean?
Idorsia (CHIX:IDIAZ) has a EBIT of CHF-67.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Idorsia.
Is Idorsia's EBIT too high?
Idorsia's current EBIT is CHF-67.2 Mil. Overall, Idorsia has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's EBIT compare to VRTX and REGN?
Idorsia's EBIT of CHF-67.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Idorsia. Idorsia's current EBIT is CHF-67.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (CHIX:IDIAZ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.88, compared to a current price of CHF6.02 — trading 109% above its estimated fair value. The current EBIT is CHF-67.2 Mil. Idorsia's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Idorsia (CHIX:IDIAZ), the current EBIT is CHF-67.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Idorsia (CHIX:IDIAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of CHF6.02 is trading 109% above its estimated GF Value™ of CHF2.88. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for CHIX:IDIAZ:

  • EBIT: CHF-67.2 Mil
  • GF Value™: CHF2.88 vs. price of CHF6.02 (109% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the CHIX:IDIAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
63GF Score

Get the complete analysis for CHIX:IDIAZ

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF6.02
Price
CHF2.88
GF Value